Table 4.

Predictors of clinical remission and endoscopic remission in CD patients with early UST use.

Predictors of treatment outcomes	Univariate analysis OR (95% CI)	p Value	Multivariate analysis OR (95% CI)	p Value
Clinical remission
Active perianal disease	3.012 (1.089–8.330)	0.034	4.809 (1.329–17.396)	0.017
Biologics exposure	2.593 (1.024–6.569)	0.044	2.374 (0.833–6.768)	0.106
CRP/ALB	2.665 (1.474–4.819)	0.001	3.350 (1.663–6.750)	<0.001
Endoscopic remission
Biologics exposure	2.579 (1.040–6.394)	0.041	2.230 (0.874–5.690)	0.093
Severe disease	3.319 (1.223–9.006)	0.018	2.930 (1.057–8.118)	0.039

Variables entered in the multivariable models before backward selection was performed included those with p < 0.1. For clinical and endoscopic remission, variables included gender, disease location, stricturing/penetrating phenotype, active perianal disease, extra-intestinal manifestations, previous intestinal resection, previous or current smoker, biologics exposure, severe disease, body mass index, and CRP/ALB.

ALB, albumin; CD, Crohn’s disease; CRP, C-reactive protein; UST, Ustekinumab.